Andrea Antinori to Humans
This is a "connection" page, showing publications Andrea Antinori has written about Humans.
Connection Strength
0.208
-
COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2. J Med Virol. 2021 03; 93(3):1796-1804.
Score: 0.007
-
Italian expert panel consensus statements on two-drug antiretroviral regimens to treat naïve and virologically suppressed HIV-1 infected patients. New Microbiol. 2019 Apr; 42(2):69-80.
Score: 0.006
-
Evidence-based renewal of the Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. New Microbiol. 2018 10; 41(4):247-255.
Score: 0.006
-
Reactivation of occult HBV infection in an HIV/HCV Co-infected patient successfully treated with sofosbuvir/ledipasvir: a case report and review of the literature. BMC Infect Dis. 2017 03 01; 17(1):182.
Score: 0.006
-
Global survey on disruption and mitigation of neurological services during COVID-19: the perspective of global international neurological patients and scientific associations. J Neurol. 2022 Jan; 269(1):26-38.
Score: 0.004
-
Age and subtle cognitive impairment are associated with long-term olfactory dysfunction after COVID-19 infection. J Am Geriatr Soc. 2021 Oct; 69(10):2778-2780.
Score: 0.004
-
Disruptions of neurological services, its causes and mitigation strategies during COVID-19: a global review. J Neurol. 2021 Nov; 268(11):3947-3960.
Score: 0.004
-
Clinical Presentation and Outcomes of Severe Acute Respiratory Syndrome Coronavirus 2-Related Encephalitis: The ENCOVID Multicenter Study. J Infect Dis. 2021 01 04; 223(1):28-37.
Score: 0.004
-
Reply to the Letter "COVID-19-Associated Encephalopathy and Cytokine-Mediated Neuroinflammation". Ann Neurol. 2020 10; 88(4):861-862.
Score: 0.004
-
Orthostatic hypotension and REM sleep behaviour disorder: impact on clinical outcomes in a-synucleinopathies. J Neurol Neurosurg Psychiatry. 2019 11; 90(11):1257-1263.
Score: 0.003
-
Extrastriatal dopaminergic and serotonergic pathways in Parkinson's disease and in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. Eur J Nucl Med Mol Imaging. 2019 Jul; 46(8):1642-1651.
Score: 0.003
-
Hypermetabolism in the cerebellum and brainstem and cortical hypometabolism are independently associated with cognitive impairment in Parkinson's disease. Eur J Nucl Med Mol Imaging. 2018 12; 45(13):2387-2395.
Score: 0.003
-
Brain-Area Specific White Matter Hyperintensities: Associations to Falls in Parkinson's Disease. J Parkinsons Dis. 2018; 8(3):455-462.
Score: 0.003
-
Cognitive impairment in Glucocerebrosidase (GBA)-associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles. Mov Disord. 2017 Dec; 32(12):1780-1783.
Score: 0.003
-
Application of the movement disorder society prodromal Parkinson's disease research criteria in 2 independent prospective cohorts. Mov Disord. 2017 Jul; 32(7):1025-1034.
Score: 0.003
-
Association between cognitive impairment and urinary dysfunction in Parkinson's disease. J Neural Transm (Vienna). 2017 05; 124(5):543-550.
Score: 0.003
-
Spontaneous ilio-psoas haematomas (IPHs): a warning for COVID-19 inpatients. Ann Med. 2021 12; 53(1):295-301.
Score: 0.002
-
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses. Clin Infect Dis. 2021 11 02; 73(9):e3019-e3026.
Score: 0.002
-
Disentangling the Association of Hydroxychloroquine Treatment with Mortality in Covid-19 Hospitalized Patients through Hierarchical Clustering. J Healthc Eng. 2021; 2021:5556207.
Score: 0.002
-
Prophylactic heparin and risk of orotracheal intubation or death in patients with mild or moderate COVID-19 pneumonia. Sci Rep. 2021 05 31; 11(1):11334.
Score: 0.002
-
SARS-CoV-2 infection and acute ischemic stroke in Lombardy, Italy. J Neurol. 2022 Jan; 269(1):1-11.
Score: 0.002
-
Role of testosterone in SARS-CoV-2 infection: A key pathogenic factor and a biomarker for severe pneumonia. Int J Infect Dis. 2021 Jul; 108:244-251.
Score: 0.002
-
Hepatic Failure in COVID-19: Is Iron Overload the Dangerous Trigger? Cells. 2021 05 04; 10(5).
Score: 0.002
-
SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus. Viruses. 2021 04 10; 13(4).
Score: 0.002
-
The multidimensional prognostic index (MPI) for the prognostic stratification of older inpatients with COVID-19: A multicenter prospective observational cohort study. Arch Gerontol Geriatr. 2021 Jul-Aug; 95:104415.
Score: 0.002
-
Impact of SARS-CoV-2 on reperfusion therapies for acute ischemic stroke in Lombardy, Italy: the STROKOVID network. J Neurol. 2021 Oct; 268(10):3561-3568.
Score: 0.002
-
Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital. Int J Infect Dis. 2021 Apr; 105:532-539.
Score: 0.002
-
In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy. J Infect. 2021 04; 82(4):58-66.
Score: 0.002
-
Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection. PLoS One. 2021; 16(2):e0247275.
Score: 0.002
-
The unbalanced p53/SIRT1 axis may impact lymphocyte homeostasis in COVID-19 patients. Int J Infect Dis. 2021 Apr; 105:49-53.
Score: 0.002
-
Co-infection of chlamydia pneumoniae and mycoplasma pneumoniae with SARS-CoV-2 is associated with more severe features. J Infect. 2021 04; 82(4):e4-e7.
Score: 0.002
-
Heparin in COVID-19 Patients Is Associated with Reduced In-Hospital Mortality: The Multicenter Italian CORIST Study. Thromb Haemost. 2021 Aug; 121(8):1054-1065.
Score: 0.002
-
COVID-19 disease-Temporal analyses of complete blood count parameters over course of illness, and relationship to patient demographics and management outcomes in survivors and non-survivors: A longitudinal descriptive cohort study. PLoS One. 2020; 15(12):e0244129.
Score: 0.002
-
An Inflammatory Profile Correlates With Decreased Frequency of Cytotoxic Cells in Coronavirus Disease 2019. Clin Infect Dis. 2020 11 19; 71(16):2272-2275.
Score: 0.002
-
Postmortem Findings in Italian Patients With COVID-19: A Descriptive Full Autopsy Study of Cases With and Without Comorbidities. J Infect Dis. 2020 11 09; 222(11):1807-1815.
Score: 0.002
-
Early expansion of myeloid-derived suppressor cells inhibits SARS-CoV-2 specific T-cell response and may predict fatal COVID-19 outcome. Cell Death Dis. 2020 10 27; 11(10):921.
Score: 0.002
-
"Early transfusion of convalescent plasma in older patients with COVID-19 to prevent disease progression: A structured summary of a study protocol for a randomised controlled trial". Trials. 2020 Oct 22; 21(1):875.
Score: 0.002
-
Frequency and Duration of SARS-CoV-2 Shedding in Oral Fluid Samples Assessed by a Modified Commercial Rapid Molecular Assay. Viruses. 2020 10 20; 12(10).
Score: 0.002
-
COVID-19 impact on consecutive neurological patients admitted to the emergency department. J Neurol Neurosurg Psychiatry. 2021 02; 92(2):218-220.
Score: 0.002
-
A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. Clin Microbiol Infect. 2021 Feb; 27(2):286.e7-286.e13.
Score: 0.002
-
Common cardiovascular risk factors and in-hospital mortality in 3,894 patients with COVID-19: survival analysis and machine learning-based findings from the multicentre Italian CORIST Study. Nutr Metab Cardiovasc Dis. 2020 10 30; 30(11):1899-1913.
Score: 0.002
-
Steroid-Responsive Encephalitis in Coronavirus Disease 2019. Ann Neurol. 2020 08; 88(2):423-427.
Score: 0.002
-
Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19). Cell Death Differ. 2020 11; 27(11):3196-3207.
Score: 0.002
-
Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy. Neurology. 2020 08 18; 95(7):e910-e920.
Score: 0.002
-
Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. J Antimicrob Chemother. 2019 11 01; 74(11):3295-3304.
Score: 0.002
-
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. J Antimicrob Chemother. 2019 09 01; 74(9):2732-2741.
Score: 0.002
-
Myeloid Derived Suppressor Cells Expansion Persists After Early ART and May Affect CD4 T Cell Recovery. Front Immunol. 2019; 10:1886.
Score: 0.002
-
Validation of the Italian version of the PSP Quality of Life questionnaire. Neurol Sci. 2019 Dec; 40(12):2587-2594.
Score: 0.002
-
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet HIV. 2019 06; 6(6):e355-e363.
Score: 0.002
-
Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. J Antimicrob Chemother. 2019 05 01; 74(5):1363-1367.
Score: 0.002
-
Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities: is it time to assess the definitions? AIDS. 2019 03 15; 33(4):759-762.
Score: 0.002
-
Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice. Virus Genes. 2019 Jun; 55(3):290-297.
Score: 0.002
-
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors. Int J Antimicrob Agents. 2019 Apr; 53(4):515-519.
Score: 0.002
-
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. J Antimicrob Chemother. 2018 12 01; 73(12):3460-3470.
Score: 0.002
-
Patient Self-Reported Adherence to Ritonavir-Boosted Darunavir Combined With Either Raltegravir or Tenofovir Disoproxil Fumarate/Emtricitabine in the NEAT001/ANRS143 Trial. J Acquir Immune Defic Syndr. 2018 12 01; 79(4):481-490.
Score: 0.002
-
New resistance mutations to nucleoside reverse transcriptase inhibitors at codon 184 of HIV-1 reverse transcriptase (M184L and M184T). Chem Biol Drug Des. 2019 01; 93(1):50-59.
Score: 0.002
-
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients. HIV Clin Trials. 2018 08; 19(4):158-162.
Score: 0.002
-
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019 01 12; 393(10167):143-155.
Score: 0.002
-
Genetic divergence of HIV-1 B subtype in Italy over the years 2003-2016 and impact on CTL escape prevalence. Sci Rep. 2018 10 24; 8(1):15739.
Score: 0.002
-
A new procedure to analyze polymorphonuclear myeloid derived suppressor cells in cryopreserved samples cells by flow cytometry. PLoS One. 2018; 13(8):e0202920.
Score: 0.002
-
Prevalence and Associated Factors of Neurocognitive Impairment in HIV-Positive Patients on Effective Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Treatment. AIDS Res Hum Retroviruses. 2018 11; 34(11):907-908.
Score: 0.002
-
A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS. 2018 07 17; 32(11):1431-1442.
Score: 0.002
-
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. J Antimicrob Chemother. 2018 07 01; 73(7):1955-1964.
Score: 0.002
-
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. BMC Med. 2018 05 29; 16(1):79.
Score: 0.002
-
Multicenter European Prevalence Study of Neurocognitive Impairment and Associated Factors in HIV Positive Patients. AIDS Behav. 2018 05; 22(5):1573-1583.
Score: 0.002
-
Impact of antiretroviral and tuberculosis therapies on CD4+ and CD8+ HIV/M. tuberculosis-specific T-cell in co-infected subjects. Immunol Lett. 2018 06; 198:33-43.
Score: 0.002
-
Resistance detected in PBMCs predicts virological rebound in HIV-1 suppressed patients switching treatment. J Clin Virol. 2018 07; 104:61-64.
Score: 0.002
-
Managing the long surviving HIV patient: a proposal for a multidimensional first-level diagnostic assessment. New Microbiol. 2018 Apr; 41(2):112-117.
Score: 0.002
-
Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. HIV Clin Trials. 2018 04; 19(2):52-60.
Score: 0.002
-
Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir ± ribavirin in HIV/HCV co-infected patients. PLoS One. 2018; 13(2):e0192627.
Score: 0.002
-
Single-subject SPM FDG-PET patterns predict risk of dementia progression in Parkinson disease. Neurology. 2018 03 20; 90(12):e1029-e1037.
Score: 0.002
-
IL-18 and Stem Cell Factor affect hematopoietic progenitor cells in HIV-infected patients treated during primary HIV infection. Cytokine. 2018 03; 103:34-37.
Score: 0.001
-
3-Year efficacy and durability of simplification to single tablet regimens: a comparison between co-formulated efavirenz/emtricitabine/tenofovir and rilpivirine/emtricitabine/tenofovir. Antivir Ther. 2018; 23(2):139-148.
Score: 0.001
-
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice. Antivir Ther. 2018; 23(3):249-257.
Score: 0.001
-
Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world. J Antimicrob Chemother. 2018 Jan 01; 73(1):160-164.
Score: 0.001
-
Serum Non-Ceruloplasmin Non-Albumin Copper Elevation in Mild Cognitive Impairment and Dementia due to Alzheimer's Disease: A Case Control Study. J Alzheimers Dis. 2018; 61(3):907-912.
Score: 0.001
-
UPLC-MS/MS method for the simultaneous quantification of sofosbuvir, sofosbuvir metabolite (GS-331007) and daclatasvir in plasma of HIV/HCV co-infected patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jan 15; 1073:183-190.
Score: 0.001
-
Brief Report: Drop in CD4+ Counts Below 200 Cells/µL After Reaching (or Starting From) Values Higher than 350 Cells/µL in HIV-Infected Patients With Virological Suppression. J Acquir Immune Defic Syndr. 2017 12 01; 76(4):417-422.
Score: 0.001
-
Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation. AIDS Patient Care STDS. 2017 Dec; 31(12):487-494.
Score: 0.001
-
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial. PLoS One. 2017; 12(11):e0187393.
Score: 0.001
-
Self-Reported Decline in Everyday Function, Cognitive Symptoms, and Cognitive Function in People With HIV. J Acquir Immune Defic Syndr. 2017 11 01; 76(3):e74-e83.
Score: 0.001
-
Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. PLoS One. 2017; 12(10):e0186549.
Score: 0.001
-
Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV/HCV co-infected patients receiving directly-acting antivirals. PLoS One. 2017; 12(10):e0187095.
Score: 0.001
-
Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: A modelling study. PLoS One. 2017; 12(10):e0186638.
Score: 0.001
-
Slow or fast viral load decay as a predictor of residual viremia level in HIV-infected patients undergoing successful first-line cART. New Microbiol. 2017 Oct; 40(4):234-241.
Score: 0.001
-
Mild Cognitive Impairment and Progression to Dementia in Progressive Supranuclear Palsy. Neurodegener Dis. 2017; 17(6):286-291.
Score: 0.001
-
Immune characterization of the HBHA-specific response in Mycobacterium tuberculosis-infected patients with or without HIV infection. PLoS One. 2017; 12(8):e0183846.
Score: 0.001
-
Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. J Acquir Immune Defic Syndr. 2017 08 01; 75(4):465-471.
Score: 0.001
-
Comparative Evaluation of Subtyping Tools for Surveillance of Newly Emerging HIV-1 Strains. J Clin Microbiol. 2017 09; 55(9):2827-2837.
Score: 0.001
-
Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI. HIV Clin Trials. 2017 07; 18(4):141-148.
Score: 0.001
-
HIV-Specific CD8 T Cells Producing CCL-4 Are Associated With Worse Immune Reconstitution During Chronic Infection. J Acquir Immune Defic Syndr. 2017 07 01; 75(3):338-344.
Score: 0.001
-
Altered brain metabolic connectivity at multiscale level in early Parkinson's disease. Sci Rep. 2017 06 26; 7(1):4256.
Score: 0.001
-
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. PLoS One. 2017; 12(5):e0177402.
Score: 0.001
-
Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA =50 cp/mL. Infection. 2017 Aug; 45(4):521-528.
Score: 0.001
-
Granulocytic Myeloid-Derived Suppressor Cells Increased in Early Phases of Primary HIV Infection Depending on TRAIL Plasma Level. J Acquir Immune Defic Syndr. 2017 04 15; 74(5):575-582.
Score: 0.001
-
In HIV/HCV co-infected patients T regulatory and myeloid-derived suppressor cells persist after successful treatment with directly acting antivirals. J Hepatol. 2017 08; 67(2):422-424.
Score: 0.001
-
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol. 2017 06; 2(6):427-434.
Score: 0.001
-
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). J Antimicrob Chemother. 2017 04 01; 72(4):1163-1171.
Score: 0.001
-
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. PLoS One. 2017; 12(2):e0171611.
Score: 0.001
-
Voluptuary Habits and Risk of Frontotemporal Dementia: A Case Control Retrospective Study. J Alzheimers Dis. 2017; 60(2):335-340.
Score: 0.001
-
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study. BMC Infect Dis. 2016 Aug 11; 16(1):401.
Score: 0.001
-
Early stage of behavioral variant frontotemporal dementia: clinical and neuroimaging correlates. Neurobiol Aging. 2015 Nov; 36(11):3108-3115.
Score: 0.001
-
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV. 2015 Mar; 2(3):e98-106.
Score: 0.001
-
Understanding phenotype variability in frontotemporal lobar degeneration due to granulin mutation. Neurobiol Aging. 2014 May; 35(5):1206-11.
Score: 0.001
-
Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study. Arch Intern Med. 2002 Dec 9-23; 162(22):2621-8.
Score: 0.001